Concord Biotech hits 52-week high after Jefferies initiates #39;buy#39; call; sees 19% upside

Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios.


http://dlvr.it/Sx44nZ